PDL’s Terlipressin Fails Phase III Trial; Company To Meet With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Late-stage development compound was evaluated for treatment of type 1 hepatorenal syndrome.
You may also be interested in...
Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma
The company will initiate a rolling NDA submission in Q2 2007 despite failure to meet novel primary endpoint, Orphan president tells “The Pink Sheet” DAILY.
Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma
The company will initiate a rolling NDA submission in Q2 2007 despite failure to meet novel primary endpoint, Orphan president tells “The Pink Sheet” DAILY.
PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals
The biotech is “aggressively” seeking potential in-licensing opportunities and hopes to partner its heart failure agent ularitide in 2007.